Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 32.28 USD 0.5% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immunocore Holdings PLC
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Total Receivables
ÂŁ61.4m
CAGR 3-Years
54%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Receivables
$39.1m
CAGR 3-Years
138%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Receivables
ÂŁ35.9m
CAGR 3-Years
77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Receivables
$24.5m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Receivables
$58m
CAGR 3-Years
96%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Receivables
ÂŁ137.3m
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
6%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

IMCR Intrinsic Value
118.25 USD
Undervaluation 73%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Total Receivables?
Total Receivables
61.4m GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Total Receivables amounts to 61.4m GBP.

What is Immunocore Holdings PLC's Total Receivables growth rate?
Total Receivables CAGR 5Y
10%

Over the last year, the Total Receivables growth was 30%. The average annual Total Receivables growth rates for Immunocore Holdings PLC have been 54% over the past three years , 10% over the past five years .

Back to Top